MAGEA4 and melanoma: Related ImmTAC molecules targeting MAGE-A4 and preferentially expressed antigen in melanoma (PRAME), cancer-testis antigens present in a broader range of malignancies, have demonstrated durable responses in early-stage clinical trials.13